Boris Shore
Presidente presso NORTHERN POTASH CO.
Posizioni attive di Boris Shore
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| NORTHERN POTASH CO. | Presidente | - | - |
| Amministratore Delegato | - | - |
Storia della carriera di Boris Shore
Precedenti posizioni note di Boris Shore
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| IMMUNE PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | - | - |
Formazione di Boris Shore
| Moscow University | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Russia | 3 |
| Stati Uniti | 2 |
Posizioni
| Chief Executive Officer | 1 |
| President | 1 |
| Undergraduate Degree | 1 |
Settori
| Process Industries | 2 |
| Consumer Services | 2 |
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| NORTHERN POTASH CO. | Process Industries |
| Aziende private | 1 |
|---|---|
Immune Pharmaceuticals, Inc.
 Immune Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Its lead product, Bertilimumab, is a human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis, and may have application in other diseases, including atopic dermatitis, asthma, and other diseases. It is also developing NanoCyclo, a topical nano-encapsulated formulation of cyclosporine, for the treatment of atopic dermatitis (AD) and psoriasis. The company was founded by Daniel Gedeon Teper on March 9, 1993 and is headquartered in Englewood Cliffs, NJ. | Health Technology |
- Borsa valori
- Insiders
- Boris Shore
- Esperienza
